WO2000065076A3 - Synthetic gene for expressing active retroviral protein in eukaryotes - Google Patents

Synthetic gene for expressing active retroviral protein in eukaryotes Download PDF

Info

Publication number
WO2000065076A3
WO2000065076A3 PCT/EP2000/003765 EP0003765W WO0065076A3 WO 2000065076 A3 WO2000065076 A3 WO 2000065076A3 EP 0003765 W EP0003765 W EP 0003765W WO 0065076 A3 WO0065076 A3 WO 0065076A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
enzyme
retroviral
gene
integrase
Prior art date
Application number
PCT/EP2000/003765
Other languages
French (fr)
Other versions
WO2000065076A2 (en
Inventor
Zeger Debyser
Clercq Erik De
Peter Cherepanov
Wim Pluymers
Original Assignee
Leuven K U Res & Dev
Zeger Debyser
Clercq Erik De
Peter Cherepanov
Wim Pluymers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leuven K U Res & Dev, Zeger Debyser, Clercq Erik De, Peter Cherepanov, Wim Pluymers filed Critical Leuven K U Res & Dev
Priority to JP2000614410A priority Critical patent/JP2002542791A/en
Priority to CA002369058A priority patent/CA2369058A1/en
Priority to EP00927069A priority patent/EP1183381A2/en
Priority to BR0010077-3A priority patent/BR0010077A/en
Priority to AU45579/00A priority patent/AU778106B2/en
Priority to IL14609000A priority patent/IL146090A0/en
Publication of WO2000065076A2 publication Critical patent/WO2000065076A2/en
Priority to NO20015168A priority patent/NO20015168L/en
Publication of WO2000065076A3 publication Critical patent/WO2000065076A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Abstract

The present invention features a synthetic gene or region of a gene which has an amended codon usage compared with the wild-type gene and which is for the high level expression of a retroviral protein in eukaryotic cells, the expressed retroviral protein having enzymatic activity in the eukaryotic cell. In addition, the invention features a synthetic gene or region of a gene encoding a retroviral enzyme or part of a retroviral enzyme normally expressed in a mammalian or other eukaryotic cell wherein at least one non-preferred codon in the wild-type gene encoding the enzyme has been replaced by a preferred codon encoding the same amino acid. The retroviral protein may be a protease, reverse transcriptase, integrase protein or a polyprotein gag-pol precursor thereof. In one embodiment the retroviral protein with enzymatic activity is a lentiviral protein. In other embodiments the enzymatically active protein is a pol enzyme. In more preferred embodiments, the enzymatically active protein is a lentiviral integrase. In an even more preferred embodiment the enzyme is an HIV enzyme. In more preferred embodiments the enzymatically active protein is HIV integrase. The present invention also includes a detection method for intracellular integrase using a promoterless reporter gene.
PCT/EP2000/003765 1999-04-26 2000-04-26 Synthetic gene for expressing active retroviral protein in eukaryotes WO2000065076A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2000614410A JP2002542791A (en) 1999-04-26 2000-04-26 Synthetic genes for expressing active retroviral proteins in eukaryotes
CA002369058A CA2369058A1 (en) 1999-04-26 2000-04-26 Synthetic gene for expressing active retroviral protein in eukaryotes
EP00927069A EP1183381A2 (en) 1999-04-26 2000-04-26 Synthetic gene for expressing active retroviral protein in eukaryotes
BR0010077-3A BR0010077A (en) 1999-04-26 2000-04-26 Synthetic gene for expression of an active retroviral protein in eukaryotes
AU45579/00A AU778106B2 (en) 1999-04-26 2000-04-26 Synthetic gene for expressing active retroviral protein in eukaryotes
IL14609000A IL146090A0 (en) 1999-04-26 2000-04-26 A synthetic gene for expression of a retroviral protein with wild type activity in eukaryotic cells
NO20015168A NO20015168L (en) 1999-04-26 2001-10-23 Synthetic gene for expression of active retroviral protein in eukaryotes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99201306 1999-04-26
EP99201306.0 2000-01-18
EP00200171 2000-01-18
EP00200171.7 2000-01-18

Publications (2)

Publication Number Publication Date
WO2000065076A2 WO2000065076A2 (en) 2000-11-02
WO2000065076A3 true WO2000065076A3 (en) 2001-12-13

Family

ID=26071747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/003765 WO2000065076A2 (en) 1999-04-26 2000-04-26 Synthetic gene for expressing active retroviral protein in eukaryotes

Country Status (11)

Country Link
EP (1) EP1183381A2 (en)
JP (1) JP2002542791A (en)
AU (1) AU778106B2 (en)
BR (1) BR0010077A (en)
CA (1) CA2369058A1 (en)
HU (1) HUP0201019A2 (en)
IL (1) IL146090A0 (en)
NO (1) NO20015168L (en)
PL (1) PL351988A1 (en)
RU (1) RU2001131728A (en)
WO (1) WO2000065076A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
EP1246913B1 (en) * 1999-12-23 2009-08-05 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Molecular clones with mutated hiv gag/pol, siv gag and siv env genes
AUPQ580300A0 (en) * 2000-02-23 2000-03-16 National Cancer Centre Of Singapore Pte Ltd Genetic analysis
GB0009760D0 (en) * 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
US6835568B2 (en) 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
US7572629B2 (en) 2003-05-06 2009-08-11 National Institute Of Advanced Industrial Science And Technology Multiple gene transcription activity assay system
US8106176B2 (en) * 2005-10-07 2012-01-31 Instituto di Richerche di Biologia Molecolare P. Angeletti SpA Matrix metalloproteinase 11 vaccine
JP6824594B2 (en) 2014-09-11 2021-02-03 Jnc株式会社 How to design synthetic genes

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434065A (en) * 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
US5468629A (en) * 1993-04-13 1995-11-21 Calhoun; Cornelia Method of promoting in vitro homologous recombination transfection in mammalian cells using the RecA protein
WO1997036481A1 (en) * 1996-04-02 1997-10-09 The Regents Of The University Of California Design of novel highly efficient hiv based packaging systems for gene therapy
WO1998012207A1 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation High level expression of proteins
WO1998034640A2 (en) * 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
US5811270A (en) * 1994-05-20 1998-09-22 Grandgenett; Duane P. In vitro method for concerted integration of donor DNA molecules using retroviral integrase proteins
WO2000039302A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358385C (en) * 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468629A (en) * 1993-04-13 1995-11-21 Calhoun; Cornelia Method of promoting in vitro homologous recombination transfection in mammalian cells using the RecA protein
US5434065A (en) * 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
US5811270A (en) * 1994-05-20 1998-09-22 Grandgenett; Duane P. In vitro method for concerted integration of donor DNA molecules using retroviral integrase proteins
WO1997036481A1 (en) * 1996-04-02 1997-10-09 The Regents Of The University Of California Design of novel highly efficient hiv based packaging systems for gene therapy
WO1998012207A1 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation High level expression of proteins
WO1998034640A2 (en) * 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
WO2000039302A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BUSHMAN, F. D. ET AL.: "Retroviral DNA integration directed by HIV integration protein in vitro", SCIENCE, vol. 249, 28 September 1990 (1990-09-28), LANCASTER, PA US, pages 1555 - 1558, XP000953086 *
CHEREPANOV P, SURRATT D, TOELEN J, PLUYMERS W, GRIFFITH J, DE CLERCQ E, DEBYSER Z.: "Activity of recombinant HIV-1 integrase on mini-HIV DNA.", NUCLEIC ACIDS RES. 1999 MAY 15;27(10):2202-10., 15 May 1999 (1999-05-15), XP000877353 *
HAAS J ET AL: "CODON USAGE LIMITATION IN THE EXPRESSION OF HIV-1 ENVELOPE GLYCOPROTEIN", CURRENT BIOLOGY,GB,CURRENT SCIENCE,, vol. 6, no. 3, 1 March 1996 (1996-03-01), pages 315 - 324, XP000619599, ISSN: 0960-9822 *
HOLLER T P ET AL: "HIV1 INTEGRASE EXPRESSED IN ESCHERICHIA COLI FROM A SYNTHETIC GENE", GENE,NL,ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, vol. 136, 22 December 1993 (1993-12-22), pages 323 - 328, XP000199775, ISSN: 0378-1119 *
KATZ, R.A. ET AL.: "The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro", CELL, vol. 63, 5 October 1990 (1990-10-05), CELL PRESS, CAMBRIDGE, NA., US, pages 87 - 95, XP000953087, ISSN: 0092-8674 *
KOTSOPOULOU E. ET AL.: "A REV-INDEPENDENT HUMAN IMMUNODEFICINCY VIRUS TYPE 1 (HIV-1)-BASED VECTOR THAT EXPLOITS A CODON OPTIMIZED HIV-1 GAG-POL GENE", JOURNAL OF VIROLOGY., vol. 74, no. 10, May 2000 (2000-05-01), ICAN SOCIETY FOR MICROBIOLOGY US, pages 4839 - 4852, XP002152133 *
SCHNEIDER R ET AL: "Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows rev-independent expression of gag and gag/protease and particle formation", JOURNAL OF VIROLOGY,THE AMERICAN SOCIETY FOR MICROBIOLOGY,US, vol. 71, no. 7, July 1997 (1997-07-01), pages 4892 - 4903, XP002137891, ISSN: 0022-538X *
ZUR MEGEDE J, CHEN MC, DOE B, SCHAEFER M, GREER CE, SELBY M, OTTEN GR, BARNETT SW: "Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.", J VIROL 2000 MAR;74(6):2628-35, XP002157414 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins

Also Published As

Publication number Publication date
BR0010077A (en) 2002-01-15
CA2369058A1 (en) 2000-11-02
AU778106B2 (en) 2004-11-18
WO2000065076A2 (en) 2000-11-02
RU2001131728A (en) 2004-02-20
EP1183381A2 (en) 2002-03-06
IL146090A0 (en) 2002-07-25
PL351988A1 (en) 2003-07-14
AU4557900A (en) 2000-11-10
JP2002542791A (en) 2002-12-17
NO20015168D0 (en) 2001-10-23
HUP0201019A2 (en) 2002-08-28
NO20015168L (en) 2001-12-14

Similar Documents

Publication Publication Date Title
WO2000065076A3 (en) Synthetic gene for expressing active retroviral protein in eukaryotes
Fusek et al. Enzymic properties of thermopsin.
Laustsen et al. Mutational analysis of the active site of human insulin‐regulated aminopeptidase
Harari et al. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H
Tanchou et al. Role of the N-terminal zinc finger of human immunodeficiency virus type 1 nucleocapsid protein in virus structure and replication
Ara et al. Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms
Pery et al. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif
HUP0301245A2 (en) Tmethod for the production of vitamin k-dependent proteins
AU4712397A (en) Lentiviral vectors
NZ509633A (en) A recombinant chimeric PEG-uricase with a long circulatory life and reduced immunogenicity
ATE450635T1 (en) ELECTROCHEMICAL PRODUCTION OF PEROXODISULFURIC ACID USING DIAMOND-COATED ELECTRODES
EP0142690A3 (en) Enzymatic toxic gas sensor
WO2001044286A3 (en) Five-helix protein
Gao et al. Replication defect of Moloney murine leukemia virus with a mutant reverse transcriptase that can incorporate ribonucleotides and deoxyribonucleotides
Baum et al. Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation
WO1995006132A3 (en) Identifying biologically active agents through culture color change
WO1998053104A3 (en) Detection of retroviral subtypes based upon envelope specific sequences
ATE339496T1 (en) MODULATION OF GAMMA SECRETASE ACTIVITY
Shapiro et al. Oxidative stress and the role of novel thiol compounds at fertilization.
Obama et al. His151 and His296 are the acid-base catalytic residues of Bacillus cereus sphingomyelinase in sphingomyelin hydrolysis
Solecka et al. Affinity of exocellular DD-carboxypeptidase/transpeptidase from Saccharopolyspora erythraea PZH TZ-575 to beta-lactam compounds
Cronn et al. RNase H activity associated with reverse transcriptase from feline immunodeficiency virus
Fhaolain et al. Turkey liver xanthine dehydrogenase. Relation between nicotinamide-adenine dinucleotide oxidoreductase activity and the content of functional enzyme.
Ferraccioli et al. Synthesis and inhibiting properties toward trypsin like proteases of N alpha-(N, N-dimethylcarbamoyl)-alpha-azaornitine and alpha-azalysine esters.
Morgan et al. Inactivation of trypsinogen by methane sulfonyl fluoride

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Kind code of ref document: A

Ref document number: 2369058

Country of ref document: CA

Ref document number: 2000 614410

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000927069

Country of ref document: EP

Ref document number: 45579/00

Country of ref document: AU

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000927069

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10019359

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000927069

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 45579/00

Country of ref document: AU